



26 July 2018

### **EQUITIES**

883 HK Price (at 06:50, 26 Jul 2018 GMT)		Outperform HK\$12.88
Valuation - 2P NPV10 (\$60-80)	HK\$	10.90-16.00
12-month target	HK\$	14.60
Upside/Downside	%	+13.4
12-month TSR	%	+17.9
GICS sector		Energy
Market cap	HK\$m	575,059
Market cap	US\$m	73,296
Free float	%	36
30-day avg turnover	US\$m	99.6
Number shares on issue	m	44,647

#### Investment fundamentals

Year end 31 Dec		2017A	2018E	2019E	2020E
Revenue	bn	186.4	227.9	199.0	233.8
EBITDA	bn	98.3	134.2	106.5	134.1
EBITDA growth	%	47.8	36.5	-20.6	26.0
EBIT	bn	37.1	69.9	40.2	64.9
EBIT growth	%	nmf	88.6	-42.5	61.4
Reported profit	bn	24.7	50.2	31.0	49.5
Adjusted profit	bn	33.1	50.2	31.0	49.5
PGCFPS	Х	5.3	3.8	4.7	3.7
EPS rep	Rmb	0.55	1.12	0.69	1.11
EPS adj	Rmb	0.74	1.12	0.69	1.11
PER adj	Х	15.0	9.9	16.0	10.0
Total DPS	Rmb	0.41	0.45	0.45	0.45
Total div yield	%	3.7	4.0	4.0	4.0
ROA	%	5.9	11.0	6.2	9.6
ROE	%	8.7	12.7	7.5	11.4
EV/EBITDA	Х	5.2	3.8	4.8	3.8
Net debt/equity	%	5.7	-2.1	-3.5	-8.9
P/BV	х	1.3	1.2	1.2	1.1

Source: FactSet, Macquarie Research, July 2018 (all figures in Rmb unless noted, TP in HKD)

### 883 HK rel HSI performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, July 2018 (all figures in Rmb unless noted, TP in HKD)

New EPS Rmb1.12/0.69/1.11, prior 1.16/0.73/1.12 for 2018/19/20e.

## Analysts

Macquarie Capital Limited



Aditya Suresh, CFA +852 3922 1265 aditya.suresh@macquarie.com

#### Hong Kong

## **CNOOC**

# \$48 EBITDA per boe, +50% EPS in 1H

### **Key points**

- ▶ We forecast CNOOC 1H18 EPS of Rmb55c, c.+50% y/y; DPS of Rmb19c.
- For every \$1 per barrel change in Brent, CNOOC's group EBITDA changes by 70 cents per boe, we estimate.
- ▶ CNOOC's FCF yield at today's share price is 9% on our estimates.

### CNOOC metrics quicklook, refer fig 1-6 for underlying trends

		2016A	1H17A	2H17A	2017A	1H18E	2H18E	2018E
Production & Realization	ıs							
Brent Oil Price	\$/bbl	43	52	57	55	71	69	70
CNOOC Oil Realization	\$/bbl	41	50	55	53	68	66	67
CNOOC Gas Realization	\$/mscf	5.5	5.7	5.6	5.8	5.7	5.7	5.7
Total O&G Production	mmboe	477	238	231	470	235	241	476
Y-o-Y change		-4%	-2%	-2%	-1%	-1%	4%	1%
% Gas		16%	17%	17%	17%	19%	19%	19%
% China		66%	66%	63%	65%	65%	65%	65%
Per Boe Metrics								
O&G Realization	\$/boe	39	46	50	48	60	58	59
Opex	\$/boe	-7	-7	-8	-8	-7	-7	-7
Production taxes	\$/boe	-2	-2	-2	-2	-3	-3	-3
Exploration	\$/boe	-2	-2	-3	-2	-2	-2	-2
DD&A	\$/boe	-22	-19	-19	-19	-20	-21	-20
Accretion expense	\$/boe	-4	0	-6	-3	-2	-2	-2
Special oil gain levy	\$/boe	0	0	0	0	0	0	0
EBIT per bbl	\$/boe	1	15	12	14	26	24	25
EBITDA per bbl	\$/boe	27	35	37	36	48	46	47
Financials								
EBITDA	Rmb. bn	66	54	44	98	65	69	134
DACF	Rmb, bn	69	49	38	86	55	59	114
EBIT	Rmb, bn	-2	22	15	37	35	35	70
Net Income, reported	Rmb, bn	1	16	8	25	25	26	50
EPS, reported	Rmb/sh	0.01	0.36	0.19	0.55	0.55	0.57	1.12
DPS	Rmb/sh	0.31	0.18	0.24	0.41	0.19	0.26	0.45
Courses Corresponded Macrosonia Decorate Lidy 2040								

Source: Company data, Macquarie Research, July 2018

- EBITDA leverage. Following the \$18/b Y/Y change in Brent, we estimate
  CNOOC's EBITDA per boe to increase by \$13 to \$48/boe in 1H18. The impact
  of the special oil gain levy kicks-in above \$65/bbl is a mere 20c/boe in
  1H18, on our estimates. Higher non-cash accretion expenses (volatile) may
  dampen our forecast EBITDA improvement, but won't derail the strong
  underlying cashflow growth.
- Guyana upside optionality. Hess and Exxon recently revised up the
  recoverable resource estimate at the Stabroek block by 25% to 4.0 billion boe,
  and noted that estimates have increased 4x since 2016. First production of
  120kb/d (gross) is expected in 2020, with scope for 750kb/d from five FPSOs
  by 2025. We carry CNOOC's 25% interest at US\$2.3bn or HK\$0.4/sh based
  on 1.5bn boe 2P (gross) and \$6.3 EV/2P, and note upside risk.
- While CNOOC has ample capacity to positively surprise on dividends, we
  model only a stable absolute payout and caution on the company's historic
  preference to allocate excess cashflow towards domestic financial products.
- We like CNOOC, but the stock falls behind Sinopec and PetroChina in our pecking order due to Macquarie's tepid oil price assumption. For perspective our 2P NAV10 for CNOOC at \$60/b LT is HK\$10.9 and at \$80/b is HK\$16.0.

### **CNOOC** in charts




Fig 2 CNOOC production outlook – stable near-term outlook; upside risk to estimates from 2020 as Stabroek (Guyana) ramps-up




Fig 3 CNOOC Realizations and Per Barrel Metrics




Fig 4 CNOOC FCF versus Dividends – ample capacity to pay a materially higher absolute dividend... but will they? In 2017 CNOOC disappointingly allocated the excess cash flow towards local financial products





Fig 5 CNOOC reserves and breakeven oil price



Source: Rystad, Company data, Macquarie Research, July 2018

26 July 2018 5

Fig 6 CNOOC financial summary

CNOOC (883 HK)									
Outperform					One-ye	ar Price	Target	HK\$14	1.60
Profit & Loss (Rmb mn)	2017A	2018E	2019E	2020E	Assumptions	2017A	2018E	2019E	2020E
Net Revenues	186,390	227,885	198,981	233,771	Rmb/US\$	6.8	6.6	6.8	6.8
COGS	-27,643	-36,981	-32,163	-37,962	Brent (US\$/bbl)	54.7	69.6	56.8	68.8
SG&A	-6,861 -46,698	-7,067 -43,732	-7,279 -46,557	-7,497 -47,153	Group Realisations	2017A	2018E	2019E	2020
Other operating costs  EBITDAX	105,188	140,106	112,981	141,159	Oil (US\$/bbl)	52.7	67.1	54.2	66.
Exploration expense	-6,881	-5,942	-6,517	-7,028	Gas (US\$/mscf)	5.8	5.7	6.1	6.3
EBITDA	98,307	134,163	106,464	134,131	Cas (CC4,co.)	0.0	0	0	0
DD&A	-61,257	-64,271	-66,268	-69,261	Production	2017A	2018E	2019E	2020
EBIT	37,050	69,893	40,196	64,870	Oil (kb/d)	1,066	1,062	1,085	1,11
Total finance costs	4,391	3,215	1,323	688	Gas (kboe/d)	218	243	250	25
Other income/(expense)	3,698	3,498	3,297	3,485	Group Production (kboe/d)	1,285	1,305	1,335	1,36
Pretax Profit	36,357	70,175	42,170	67,667	Production Growth Y/Y %	-1%	1%	2%	2%
Tax Expense	-11,680	-19,973	-11,146	-18,202	1,500 n CNOOC Oil	& Gas Produc	tion Outlook		<sub>г</sub> 25%
Reported Net Income	24,677	50,203	31,024	49,466	1,500				20%
Clean Net Income	33,088	50,203	31,024	49,466	1,000 -				15%
Reported EPS (Rmb/sh)	0.55	1.12	0.69	1.11	500 -				- 10%
Clean EPS (Rmb/sh) DPS (Rmb/sh)	0.74 0.41	1.12 0.45	0.69 0.45	1.11 0.45	Oil	Gas —	─% of gas - rhs		- 5%
or o (itilib/sil)	0.41	0.43	0.43	0.43	0 4 4 4 4 4				₩ 0%
Cashflows (Rmb mn)	2017A	2018E	2019E	2020E	LOBER LOBER STOR SOUL LOVER L	13A 201AA 2015A	2016A 2017A	101.8K 101.9K 101	<i>y</i> .
EBITDA	98,307	134,163	106,464	134,131	B	00474	00405	00405	0000
ess Tax Paid	15,891	19,973 0	11,146 0	18,202 0	Reserves	2017A	2018E	2019E	2020
ess Chgs in Working Cap add Other	-14,038 1,730	_	-	-	1P Reserves (mboe) 1P Reserve Life (yrs)	3,902	3,723	3,602 7.4	3,45 6.
Operating Cashflow	-1,720 <b>94,734</b>	2,409 <b>116,600</b>	2,409 <b>97,728</b>	2,409 <b>118,338</b>	EV / 1P reserves (US\$/boe)	8.3 24.6	7.8 24.7	7.4 25.1	25.
Acquisitions	94,734	0	91,120	110,330	EV / TP Teserves (US\$/b0e)	24.0	24.7	23.1	23.
Capex	-47,734	-65,000	-70,000	-75,000	Per barrel statistics (US\$/bo	2017A	2018E	2019E	2020E
Asset Sales	-203	0	0	0	Realizations	47.6	59.0	48.5	56.2
Other	-16,474	2,502	4,194	5,017	Opex	-7.6	-7.4	-8.0	-7.8
Investing Cashflow	-64,411	-62,498	-65,806	-69,983	Production Tax	-2.3	-2.9	-2.7	-2.6
Dividends Paid	-16,448	-19,145	-21,300	-18,219	Exploration Expense	-2.2	-1.9	-2.0	-2.
Debt Raised	12,252	0	0	0	DD&A	-19.2	-20.5	-20.0	-20.
Other	-27,075	-4,629	-4,629	-4,629	Accretion expense	-2.9	-1.6	-1.6	-1.6
Financial Cashflow	-31,271	-23,773	-25,928	-22,848	Special oil gain levy	0.0	-0.1	0.0	-0.2
FCF: CFO Canay	47.000	51,600	27 720	42 220	EBIT	13.5	24.5	14.3	21.4
FCF: CFO - Capex CFO - Capex - Dividends	47,000 30,552	32,455	27,728 6,428	43,338 25,119	Income Tax Net Income	-3.7 <b>9.8</b>	-6.4 <b>18.2</b>	-3.4 <b>11.0</b>	-5.4 <b>16.</b> 0
CFO - Capex - Dividends	30,332	32,433	0,420	25,119	EBITDA	35.6	46.7	35.9	43.
Balance Sheet (Rmb mn)	2017A	2018E	2019E	2020E	DACF	31.9	40.7	32.5	38.
Cash & Cash eqv.	12,572	42,901	48,894	74,402	DAGI	31.3	40.5	32.3	50.
Current assets	138,838	169,167	175,160	200,668	Valuation	2017A	2018E	2019E	2020E
Fixed assets	478,381	479,110	482,842	488,581	EV/EBITDA	6.6x	4.5x	5.8x	4.4
Total Assets	617,219	648,277	658,002	689,249	EV/DACF	6.4x	4.9x	5.9x	4.7
Current Liabilities	61,412	61,412	61,412	61,412	P/E	20.0x	9.5x	15.9x	10.0
Non-Current Liabilities	175,832	176,779	175,571	177,443	P/B	1.3x	1.2x	1.2x	1.1:
Shareholder Equity	379,975	410,086	421,019	450,394	2P Oil & Gas Reserves versus Break	even Oil Price			
Net debt/(cash)	157,191	126,862	120,869	95,361	2P NPV10 (US\$, million) € 6.0 ≤ 0				
Ratios	2017A	2018E	2019E	2020E	(a 6.0				
Gearing (ND/ND&E)	29%	24%	22%	17%	5 4.0 20,000		Bohai Bay		
Interest Cover	19x	29x	23x	29x	3.0				
Effective Tax Rate	32%	28%	26%	27%	elli o o				
ROE	6%	12%	7%	11%	(a) 2.0 62	Pearl River Mouth			Santos
	5%	10%	6%	10%	1.0	) West Java		Moray Firth	Niger Delta
ROACE		12%	10%	11%	0.0 Belbu G			GoM	50
	10%	12/0	.0,0	, .	0 5 10 15	20 25	30 35	40 45	
ROACE CROCE FCF yield	10% 7.2%	8.5%	4.5%	7.3%		20 25 Break-Even Oil @ 10%		40 45	30
CROCE								40 45	30

## **Macquarie Quant View**

The quant model currently holds a strong positive view on CNOOC. The strongest style exposure is Earnings Momentum, indicating this stock has received earnings upgrades and is well liked by sell side analysts. The weakest style exposure is Profitability, indicating this stock is not efficiently converting investments to earnings; proxied by ratios like ROE or ROA.

## 18/606

Global rank in

Energy

% of BUY recommendations 83% (19/23)

Number of Price Target downgrades 0 Number of Price Target upgrades 9




Displays where the company's ranked based on the fundamental consensus Price Target and Macquarie's Quantitative Alpha model.

Two rankings: Local market (Hong Kong) and Global sector (Energy)

## Macquarie Alpha Model ranking


A list of comparable companies and their Macquarie Alpha model score (higher is better).



### **Factors driving the Alpha Model**


For the comparable firms this chart shows the key underlying styles and their contribution to the current overall Alpha score.

Attractive




### **Macquarie Earnings Sentiment Indicator**

The Macquarie Sentiment Indicator is an enhanced earnings revisions signal that favours analysts who have more timely and higher conviction revisions. Current score shown below.




### **Drivers of Stock Return**

Breakdown of 1 year total return (local currency) into returns from dividends, changes in forward earnings estimates and the resulting change in earnings multiple.




### What drove this Company in the last 5 years

Which factor score has had the greatest correlation with the company's returns over the last 5 years.



### How it looks on the Alpha model

A more granular view of the underlying style scores that drive the alpha (higher is better) and the percentile rank relative to the sector and market.



Source (all charts): FactSet, Thomson Reuters, and Macquarie Research. For more details on the Macquarie Alpha model or for more customised analysis and screens, please contact the Macquarie Global Quantitative/Custom Products Group (<a href="mailto:cpg@macquarie.com">cpg@macquarie.com</a>)

CNOOC (883 HK, Outperform, Target Price: HK\$14.60)

Interim Results	преттог	2H/17A	1H/18E	2H/18E	1H/19E	Profit & Loss		2017A	2018E	2019E	2020E
Revenue	m	94,028	110,630	117,255	98,025	Revenue	m	186,390	227,885	198,981	233,771
Gross Profit	m	59,274	74,442	78,246	61,470	Gross Profit	m	120,374	152,688	124,899	153,565
Cost of Goods Sold	m	34,754	36,188	39,010	36,555	Cost of Goods Sold	m	66,016	75,197	74,081	80,206
EBITDA	m	44,398	65,149	69,015	52,272	EBITDA	m	98,307	134,163	106,464	134,131
Depreciation	m	29,433	30,476	33,795	32,538	Depreciation	m	61,257	64,271	66,268	69,261
Amortisation of Goodwill	m	0	0	0	0	Amortisation of Goodwill	m	0	0	0	0
Other Amortisation	m	0	0	0	0	Other Amortisation	m	0	0	0	0
EBIT	m	14,965	34,673	35,219	19,734	EBIT	m	37,050	69,893	40,196	64,870
Net Interest Income	m	-1,996	-1,837	-1,378	-686	Net Interest Income	m	-4,391	-3,215	-1,323	-688
Associates	m	414 -8,400	544 0	544 0	444 0	Associates Exceptionals	m	855 -8,411	1,089 0	888 0	1,076 0
Exceptionals Forex Gains / Losses	m m	-6, <del>4</del> 00	0	0	0	Forex Gains / Losses	m m	356	0	0	0
Other Pre-Tax Income	m	9,796	1,205	1,205	1,205	Other Pre-Tax Income	m	10,898	2,409	2,409	2,409
Pre-Tax Profit	m	14,841	34,585	35,590	20,696	Pre-Tax Profit	m	<b>36,357</b>	70,175	42,170	67,667
Tax Expense	m	-6,414	-9,959	-10,014	-5,496	Tax Expense	m	-11,680	-19,973	-11,146	-18,202
Net Profit	m	8,427	24,626	25,577	15,201	Net Profit	m	24,677	50,203	31,024	49,466
Minority Interests	m	0	0	0	0	Minority Interests	m	0	0	0	0
Reported Earnings Adjusted Earnings	m m	8,427 16,827	24,626 24,626	25,577 25,577	15,201 15,201	Reported Earnings Adjusted Earnings	m m	24,677 33,088	50,203 50,203	31,024 31,024	49,466 49,466
EPS (rep)		0.19	0.55	0.57	0.34	EPS (rep)		0.55	1.12	0.69	1.11
EPS (adj)		0.38	0.55	0.57	0.34	EPS (adj)		0.74	1.12	0.69	1.11
EPS Growth yoy (adj)	%	164.1	51.4	52.0	-38.3	EPS Growth (adj)	%	550.8	51.7	-38.2	59.4
						PE (rep)	Х	20.1	9.9	16.0	10.0
						PE (adj)	Х	15.0	9.9	16.0	10.0
EBITDA Margin	%	47.2	58.9	58.9	53.3	Total DPS	07	0.41	0.45	0.45	0.45
EBIT Margin	%	15.9	31.3	30.0	20.1	Total Div Yield	%	3.7	4.0	4.0	4.0
Earnings Split Revenue Growth	% %	50.9 18.0	49.1 19.8	50.9	49.0 -11.4	Basic Shares Outstanding Diluted Shares Outstanding	m	44,647	44,647	44,647 44,647	44,647
EBIT Growth	%	78.5	57.0	24.7 135.3	-11. <del>4</del> -43.1	Diluted Shares Outstanding	m	44,647	44,647	44,047	44,647
Profit and Loss Ratios		2017A	2018E	2019E	2020E	Cashflow Analysis		2017A	2018E	2019E	2020E
Revenue Growth	%	27.2	22.3	-12.7	17.5	EBITDA	m	98,307	134,163	106,464	134,131
EBITDA Growth	%	47.8	36.5	-12.7 -20.6	26.0	Tax Paid	m	0	-19,973	-11,146	-18,202
EBIT Growth	%	nmf	88.6	-42.5	61.4	Chgs in Working Cap	m	0	0	0	0
Gross Profit Margin	%	64.6	67.0	62.8	65.7	Net Interest Paid	m	0	3,215	1,323	688
EBITDA Margin	%	52.7	58.9	53.5	57.4	Other	m	-3,573	-806	1,086	1,721
EBIT Margin	%	19.9	30.7	20.2	27.7	Operating Cashflow	m	94,734	116,600	97,728	118,338
Net Profit Margin	%	17.8	22.0	15.6	21.2	Acquisitions	m	0	0	0	0
Payout Ratio	%	55.7	40.0	64.8	40.6	Capex	m	-47,734	-65,000	-70,000	-75,000
EV/EBITDA	Х	5.2	3.8	4.8	3.8	Asset Sales	m	0	0	0	0
EV/EBIT	Х	13.7	7.3	12.6	7.9	Other	m	-16,677	2,502	4,194	5,017
						Investing Cashflow	m	-64,411	-62,498	-65,806	-69,983
Balance Sheet Ratios						Dividend (Ordinary)	m	0	-19,145	-21,300	-18,219
ROE	%	8.7	12.7	7.5	11.4	Equity Raised	m	0	0	0	0
ROA ROIC	% %	5.9 5.7	11.0	6.2 7.4	9.6	Debt Movements Other	m	0 24 271	4 620	4 620	4 620
Net Debt/Equity	%	5.7 5.7	12.5 -2.1	-3.5	11.7 -8.9	Financing Cashflow	m <b>m</b>	-31,271 <b>-31,271</b>	-4,629 <b>-23,773</b>	-4,629 <b>-25,928</b>	-4,629 <b>-22,848</b>
Interest Cover	/6 X	8.4	21.7	30.4	94.3	Financing Cashilow	""	-31,271	-23,773	-23,326	-22,040
Price/Book	x	1.3	1.2	1.2	1.1	Net Chg in Cash/Debt	m	-948	30,329	5,993	25,507
Book Value per Share		8.5	9.2	9.4	10.1	Free Cashflow	m	47,000	51,600	27,728	43,338
						Balance Sheet		2017A	2018E	2019E	2020E
						Cash	m	110,683	141,012	147,005	172,513
						Receivables	m	20,787	20,787	20,787	20,787
						Inventories	m	7,354	7,354	7,354	7,354
						Investments	m	28,633	28,633	28,633	28,633
						Fixed Assets	m	395,868	396,597	400,329	406,068
						Intangibles	m	15,070	15,070	15,070	15,070
						Other Assets	m	38,824	38,824	38,824	38,824
						Total Assets	m	617,219	648,277	658,002	689,249
						Payables Short Term Debt	m m	40,819	40,819	40,819 13.892	40,819
						Long Term Debt	m m	13,892 118,358	13,892 118,358	13,892	13,892 118,358
						Provisions	m	52,893	52,893	52,893	52,893
						Other Liabilities	m	11,282	12,229	11,021	12,893
						Total Liabilities	m	237,244	238,191	236,983	238,855
						Shareholders' Funds	m	379,975	410,086	421,019	450,394
						Minority Interests	m	0	0	0	0
						Other	m	0	0	0	0
						Total S/H Equity Total Liab & S/H Funds	m m	379,975 617,219	410,086 648,277	421,019 658,002	450,394 689,249
AU.C						Total Elab & Offi Fullus		511,213	0-70,E11	000,002	553,£43
All figures in Rmb unless no Source: Company data, Mac		esearch, Jul	y 2018								

#### Important disclosures:

#### Recommendation definitions

#### Macquarie - Australia/New Zealand

Outperform - return >3% in excess of benchmark return Neutral - return within 3% of benchmark return Underperform - return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield, which is currently around 9%.

### Macquarie - Asia/Europe

Outperform - expected return >+10% Neutral - expected return from -10% to +10% Underperform – expected return <-10%

#### Macquarie - South Africa

Outperform - expected return >+10% Neutral - expected return from -10% to +10% Underperform - expected return <-10%

#### Macquarie - Canada

Outperform - return >5% in excess of benchmark return Neutral - return within 5% of benchmark return Underperform - return >5% below benchmark return

#### Macquarie - USA

Outperform (Buy) - return >5% in excess of Russell 3000 index return

Neutral (Hold) - return within 5% of Russell 3000 index

Underperform (Sell)- return >5% below Russell 3000 index return

### Volatility index definition\*

This is calculated from the volatility of historical price movements

Very high-highest risk - Stock should be expected to move up or down 60-100% in a year - investors should be aware this stock is highly speculative.

High - stock should be expected to move up or down at least 40-60% in a year - investors should be aware this stock could be speculative.

Medium - stock should be expected to move up or down at least 30-40% in a year.

Low-medium - stock should be expected to move up or down at least 25-30% in a year.

Low - stock should be expected to move up or down at least 15-25% in a year.

\* Applicable to Asia/Australian/NZ/Canada stocks only

Recommendations - 12 months Note: Quant recommendations may differ from Fundamental Analyst recommendations

#### Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

EPS = adjusted net profit / efpowa\* ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average

**ROE** = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation \*equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

### Recommendation proportions - For quarter ending 30 June 2018

	AU/NZ	Asia	RSA	USA	CA	EUR
Outperform	52.87%	61.26%	48.86%	47.54%	69.86%	46.61%
Neutral	34.10%	27.25%	36.36%	46.72%	21.92%	43.22%
Underperform	13.03%	11.49%	14.77%	5.74%	8.22%	10.17%
'						

(for global coverage by Macquarie, 3.51% of stocks followed are investment banking clients) (for global coverage by Macquarie, 2.10% of stocks followed are investment banking clients) (for global coverage by Macquarie, 0.00% of stocks followed are investment banking clients)

### 883 HK vs HSI, & rec history



(all figures in HKD currency unless noted)



(all figures in HKD currency unless noted)



(all figures in HKD currency unless noted)

Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, July 2018

### 12-month target price methodology

883 HK: HK\$14.60 based on a 2P NPV10 methodology

2386 HK: HK\$9.70 based on a EV/EBITDA methodology

857 HK: HK\$7.70 based on a Sum of Parts methodology

### Company-specific disclosures:

883 HK: Macquarie Capital Limited makes a market in the securities of CNOOC Ltd. 2386 HK: Macquarie Capital Limited makes a market in the securities of SINOPEC Engineering Group Co Ltd. 857 HK: Macquarie Capital Limited makes a market in the securities of PetroChina Co Ltd. Important disclosure information regarding the subject companies covered in this report is available at <a href="https://www.macquarie.com/research/disclosures">www.macquarie.com/research/disclosures</a>.

Date	Stock Code (BBG code)	Recommendation	Target Price
26-Apr-2018	883 HK	Outperform	HK\$14.60
12-Feb-2018	883 HK	Outperform	HK\$12.50
09-Jan-2018	883 HK	Neutral	HK\$12.50
14-Dec-2017	883 HK	Outperform	HK\$12.50
04-Oct-2017	883 HK	Outperform	HK\$11.50
25-Aug-2017	883 HK	Outperform	HK\$11.00
21-Jun-2017	883 HK	Outperform	HK\$9.50
24-Mar-2017	883 HK	Outperform	HK\$11.00
03-Feb-2017	883 HK	Neutral	HK\$10.00
25-Jan-2017	883 HK	Outperform	HK\$12.00
07-Nov-2016	883 HK	Outperform	HK\$13.50
25-Aug-2016	883 HK	Outperform	HK\$14.00
25-Jul-2016	883 HK	Outperform	HK\$13.50
14-Mar-2016	883 HK	Outperform	HK\$13.00
08-Jan-2016	883 HK	Outperform	HK\$11.00
12-Nov-2015	883 HK	Outperform	HK\$12.00
09-Sep-2015	883 HK	Outperform	HK\$13.00

26 July 2018 9

### Target price risk disclosures:

883 HK: Oil price volatility.

2386 HK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures. In particular for SEG, itis exposed to SOE political risks, unexpected changes in parent (and key client) Sinopec's strategy, changes in regulations that alter clients refining, petchems and new coal investment plans, anti-corruption investigation disrupting operations and the inherent operational and HSE risks from bdesigning and building very large oilfield projects.

857 HK: Oil price volatility. Potential cut to China's gas price and pipeline tariffs.

### Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

### General disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie Equities South Africa (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research.

### Country-specific disclaimers:

Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organization of the Australian Securities Exchange. Macquarie Securities (Australia) Limited staff involved with the preparation of research have regular interaction with companies they cover. Additionally, Macquarie Group Limited does and seeks to do business with companies covered by Macquarie Research. There are robust information barriers in place to protect the independence of Macquarie Research's product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd., a (i) member of the Investment Industry Regulatory Organization of Canada and the Canadian Investor Protection Fund, and (ii) participating organization of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. This research is distributed in the United States, as third party research by Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of Financial Industry Regulatory Authority and the Securities Investor Protection Corporation. Macquarie Capital Markets North America Ltd. accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd. in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd. should do so with Macquarie Capital Markets North America Ltd. This research is intended for distribution in the United States only to major Institutional Investors (as such term is defined in SEC 15a-6 and Section 15 of the Securities Exchange Act of 1934, as amended) and is not intended for the use of any person or entity that is not a major institutional investor. Research analysts of Macquarie Capital Markets Canada Ltd. are not registered/qualified as research analysts with FINRA. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd. is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. **Taiwan**: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed

securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websguare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=MDIS03002001000000&serviceId=SDIS03002 001000. South Africa: In South Africa, research is issued and distributed by Macquarie Equities South Africa (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie Equities South Africa (Pty) Ltd and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc., accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019.

© Macquarie Group



### **Equities**

## **Asia Research**

Head of Equity R	esearch
------------------	---------

Jake Lynch (Asia - Head)	(852) 3922 3583
Hiroyuki Sakaida (Japan - Head)	(813) 3512 6695
Conrad Werner (ASEAN - Head)	(65) 6601 0182

#### Automobiles, Auto Parts

 Janet Lewis (China, Japan)
 (813) 3512 7856

 Allen Yuan (China)
 (8621) 2412 9009

 James Hong (Korea)
 (822) 3705 8661

 Amit Mishra (India)
 (9122) 6720 4084

### **Banks and Financials**

Scott Russell (Asia) (852) 3922 3567 Dexter Hsu (China, Taiwan) (8862) 2734 7530 Keisuke Moriyama (Japan) (813) 3512 7476 Chan Hwang (Korea) (822) 3705 8643 Suresh Ganapathy (India) (9122) 6720 4078 Jayden Vantarakis (Indonesia) (6221) 2598 8310 Anand Pathmakanthan (Malaysia) (603) 2059 8833 Gilbert Lopez (Philippines) (632) 857 0892 Ken Ang (Singapore) Peach Patharavanakul (Thailand) (65) 6601 0836 (662) 694 7753

#### **Basic Materials**

 Yasuhiro Nakada (Japan)
 (813) 3512 7862

 Anna Park (Korea)
 (822) 3705 8669

 Sumangal Nevatia (India)
 (9122) 6720 4093

 Jayden Vantarakis (Indonesia)
 (6221) 2598 8310

 Farrah Aqlima (Malaysia)
 (603) 2059 8987

#### Conglomerates

 David Ng (China, Hong Kong)
 (852) 3922 1291

 Conrad Werner (Singapore)
 (65) 6601 0182

 Gilbert Lopez (Philippines)
 (632) 857 0892

### Consumer, Gaming

(852) 3922 4068 Linda Huang (Asia) (852) 3922 1130 Zibo Chen (China, Hong Kong) Terence Chang (China, Hong Kong) (852) 3922 3581 Sunny Chow (China, Hong Kong) Stella Li (China, Taiwan) (852) 3922 3768 (8862) 2734 7514 Leon Rapp (Japan) (813) 3512 7879 Kwang Cho (Korea) (822) 3705 4953 Amit Sinha (India) (9122) 6720 4085 Karisa Magpayo (Philippines)
Chalinee Congmuang (Thailand) (632) 857 0899 (662) 694 7993 Robert Pranata (Indonesia) (6221) 2598 8366 Richardo Walujo (Indonesia) (6221) 2598 8369 Denise Soon (Malaysia) (603) 2059 8845

### **Emerging Leaders**

 Jake Lynch (Asia)
 (852) 3922 3583

 Kwang Cho (Korea)
 (822) 3705 4953

 Corinne Jian (Greater China)
 (8862) 2734 7522

 Conrad Werner (ASEAN)
 (65) 6601 0182

 Bo Denworalak (Thailand)
 (662) 694 7774

### Infrastructure, Industrials, Transportation

 Patrick Dai (China)
 (8621) 2412 9082

 Eric Zong (China, Hong Kong)
 (852) 3922 4749

 Kunio Sakaida (Japan)
 (813) 3512 7873

 James Hong (Korea)
 (822) 3705 8661

 Corinne Jian (Taiwan)
 (8862) 2734 7522

 Inderjeetsingh Bhatia (India)
 (9122) 6720 4087

 Azita Nazrene (ASEAN)
 (65) 6601 0560

#### Internet, Media and Software

 Wendy Huang (Asia)
 (852) 3922 3378

 Marcus Yang (Greater China)
 (8862) 2734 7532

 David Gibson (Japan)
 (813) 3512 7880

 Alankar Garude (India)
 (9122) 6720 4134

### Oil, Gas and Petrochemicals

 Aditya Suresh (Asia)
 (852) 3922 1265

 Anna Park (Asia)
 (822) 3705 8669

 Yasuhiro Nakada (Japan)
 (813) 3512 7862

 Corinne Jian (Taiwan)
 (8862) 2734 7522

 Ben Shane Lim (Malaysia)
 (603) 2059 8868

 Yupapan Polpornprasert (Thailand)
 (662) 694 7729

#### Pharmaceuticals and Healthcare

 Corinne Jian (China)
 (8862) 2734 7522

 Alankar Garude (India)
 (9122) 6720 4134

 Richardo Walujo (Indonesia)
 (6221) 259 88 369

### Property, REIT

Tuck Yin Soong (Asia, Singapore) (65) 6601 0838 David Ng (China, Hong Kong) (852) 3922 1291 Kelvin Tam (China) (852) 3922 1181 (813) 3512 7476 (813) 3512 7474 Keisuke Moriyama (Japan) Tomovoshi Omuro (Japan) Abhishek Bhandari (India) (9122) 6720 4088 (603) 2059 8986 Aiman Mohamad (Malaysia) Kervin Sisayan (Philippines) (632) 857 0893 Richard Danusaputra (Indonesia) (6221) 2598 8368

### Technology

Damian Thong (Asia, Japan) (813) 3512 7877 Allen Chang (Greater China) (852) 3922 1136 Jeffrey Ohlweiler (Greater China) (8862) 2734 7512 Chris Yu (Greater China) (8621) 2412 9024 Kaylin Tsai (Greater China) (8862) 2734 7523 Lynn Luo (Greater China) (8862) 2734 7534 (8862) 2734 7515 Patrick Liao (Greater China) Verena Jeng (Greater China) (852) 3922 3766 Daniel Kim (Korea) (822) 3705 8641 (9122) 6720 4088 (603) 2059 8987 Abhishek Bhandari (India) Farrah Aqlima (Malaysia)

#### **Telecoms**

Allen Chang (Greater China) Prem Jearajasingam (ASEAN) Kervin Sisayan (Philippines) Nathania Nurhalim (Indonesia) (852) 3922 1136 (603) 2059 8989 (632) 857 0893 (6221) 2598 8365

### **Utilities, Renewables**

 Hiroyuki Sakaida (Japan)
 (813) 3512 6695

 Patrick Dai (China)
 (8621) 2412 9082

 Inderjeetsingh Bhatia (India)
 (9122) 6720 4087

 Karisa Magpayo (Philippines)
 (632) 857 0899

### Quantitative, CPG

 Gurvinder Brar (Global)
 (44 20) 3037 4036

 John Conomos (Asia)
 (612) 8232 5157

 Alvin Chao (Asia)
 (852) 3922 1108

 Tracy Chow (Asia)
 (852) 3922 4285

 Ying Ying Hou (Asia)
 (852) 3922 5422

### Strategy, Country

Viktor Shvets (Asia, Global)
David Ng (China, Hong Kong)
Hiroyuki Sakaida (Japan)
Chan Hwang (Korea)
Jeffrey Ohlweiler (Taiwan)
Inderjeetsingh Bhatia (India)
Jayden Vantarakis (Indonesia)
Anand Pathmakanthan (Malaysia)
Gilbert Lopez (Philippines)
Conrad Werner (ASEAN, Singapore)
Peach Patharavanakul (Thailand)

(632) 857 0892

(65) 6601 0182

(662) 694 7753

### Find our research at

Macquarie: www.macquarieresearch.com
Thomson: www.thomson.com/financial
www.knowledge.reuters.com
MAC GO

Factset: http://www.factset.com/home.aspx

CapitalIQ www.capitaliq.com
Email macresearch@macquarie.com for access

### **Asia Sales**

### Regional Heads of Sales

Miki Edelman (Global) (1 212) 231 6121 Amelia Mehta (Asia) (65) 6601 0211 Jeffrey Shiu (China, Hong Kong) (852) 3922 2061 Sandeep Bhatia (India) (9122) 6720 4101 (41 22) 818 7712 Thomas Renz (Geneva) (813) 3512 7823 Tomohiro Takahashi (Japan) John Jay Lee (Korea) (822) 3705 9988 Nik Hadi (Malaysia) (603) 2059 8888 Gino C Rojas (Philippines) (632) 857 0861

### Regional Heads of Sales cont'd

 Paul Colaco (San Francisco)
 (1 415) 762 5003

 Angus Kent (Thailand)
 (662) 694 7601

 Ben Musgrave (UK/Europe)
 (44 20) 3037 4882

 Christina Lee (UK/Europe)
 (44 20) 3037 4873

### **Sales Trading**

Adam Zaki (Asia) (852) 3922 2002 Stanley Dunda (Indonesia) (6221) 515 1555

### Sales Trading cont'd

 Suhaida Samsudin (Malaysia)
 (603

 Michael Santos (Philippines)
 (632

 Chris Reale (New York)
 (1 21

 Marc Rosa (New York)
 (1 21

 Justin Morrison (Singapore)
 (65)

 Daniel Clarke (Taiwan)
 (886

 Brendan Rake (Thailand)
 (662

 Mike Keen (UK/Europe)
 (44 2

(603) 2059 8888 (632) 857 0813 (1 212) 231 2555 (1 212) 231 2555 (5601 0288 (8862) 2734 7580 (662) 694 7707 (44 20) 3037 4905